Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6% - Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares dropped 6% during trading on Wednesday . The company traded as low as $17.61 and last traded at $17.06. Approximately 3,638 shares were traded during trading, a decline of 99% from the average daily volume of 274,140 shares. The stock had previously closed at $18.14.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, Robert W. Baird reduced their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Performance

The company's 50-day moving average is $19.12 and its 200 day moving average is $20.65. The company has a market capitalization of $566.98 million, a PE ratio of -6.12 and a beta of 1.36.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,544.23% and a negative return on equity of 29.26%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. On average, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. US Bancorp DE lifted its stake in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after acquiring an additional 1,510 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $33,000. BNP Paribas Financial Markets purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth $59,000. GAMMA Investing LLC grew its holdings in shares of Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after acquiring an additional 3,758 shares during the period. Finally, AlphaQuest LLC increased its position in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after acquiring an additional 3,072 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.